{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T12:42:15Z","timestamp":1703853735317},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>We present the case of a 75-year-old man diagnosed with myasthenia gravis (MG) based on lower leg weakness and ptosis for the past 2\u2009months before admission to our hospital. The patient was anti-acetylcholine receptor antibody\u2013positive at admission. He was treated with pyridostigmine bromide and prednisolone, which improved the ptosis, but the lower leg muscle weakness remained. An additional lower leg magnetic resonance imaging examination suggested myositis. Inclusion body myositis (IBM) was diagnosed after a subsequent muscle biopsy. Although MG is often associated with inflammatory myopathy, IBM is rare. There is no effective treatment for IBM, but various treatment possibilities have recently been proposed. This case emphasises that myositis complications, including IBM, should be considered when elevated creatine kinase levels are observed and conventional treatments do not address chronic muscle weakness.<\/jats:p>","DOI":"10.1093\/mrcr\/rxad026","type":"journal-article","created":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T00:57:15Z","timestamp":1684630635000},"page":"83-85","source":"Crossref","is-referenced-by-count":0,"title":["Myasthenia gravis with inclusion body myositis: A case report"],"prefix":"10.1093","volume":"8","author":[{"given":"Takuya","family":"Kakutani","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Shonan Kamakura General Hospital , Kamakura city, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Shonan Kamakura General Hospital , Kamakura city, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"2023122911392330900_R1","first-page":"1","article-title":"Myasthenia gravis","volume":"30","author":"Gilhus","year":"2019","journal-title":"Nat Rev"},{"key":"2023122911392330900_R2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: Clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2023122911392330900_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2020.102498","article-title":"Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of myasthenia-myositis association from a large cohort of patients","volume":"19","author":"Garibaldi","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2023122911392330900_R4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.semarthrit.2018.05.004","article-title":"Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: A case series and literature review","volume":"48","author":"Huang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2023122911392330900_R5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.nmd.2019.09.004","article-title":"A novel case of inclusion body myositis and myasthenia gravis","volume":"29","author":"Lambrianides","year":"2019","journal-title":"Neuromuscul Dis"},{"key":"2023122911392330900_R6","first-page":"1","article-title":"Treatment for inclusion body myositis (review)","volume":"6","author":"Rose","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2023122911392330900_R7","doi-asserted-by":"crossref","first-page":"e1374","DOI":"10.1212\/WNL.0000000000200013","article-title":"Immunophenotyping of inclusion body myositis blood T and NK cells","volume":"98","author":"Goyal","year":"2022","journal-title":"Neurology"},{"key":"2023122911392330900_R8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxad026\/50487315\/rxad026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/1\/83\/54920110\/rxad026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/1\/83\/54920110\/rxad026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T12:27:52Z","timestamp":1703852872000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/8\/1\/83\/7175021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,20]]},"published-print":{"date-parts":[[2023,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxad026","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,5,20]]}}}